<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To determine if the dipeptidyl peptidase-4 inhibitor vildagliptin more effectively inhibits glucagon levels than the <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi> <z:chebi fb="0" ids="5383">glimepiride</z:chebi> during a meal </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: Glucagon responses to a standard meal were measured at baseline and study end point (mean 1.8 years) in a trial evaluating add-on therapy to <z:chebi fb="0" ids="6801">metformin</z:chebi> with 50 mg vildagliptin b.i.d. compared with <z:chebi fb="0" ids="5383">glimepiride</z:chebi> up to 6 mg q.d. in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (baseline A1C 7.3 +/- 0.6%) </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: A1C and prandial <z:chebi fb="105" ids="17234">glucose</z:chebi> area under the curve (AUC)(0-2 h) were reduced similarly in both groups, whereas prandial insulin AUC(0-2 h) increased to a greater extent by <z:chebi fb="0" ids="5383">glimepiride</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>Prandial glucagon AUC(0-2 h) (baseline 66.6 +/- 2.3 pmol  </plain></SENT>
<SENT sid="4" pm="."><plain>h(-1)  </plain></SENT>
<SENT sid="5" pm="."><plain>l(-1)) decreased by 3.4 +/- 1.6 pmol  </plain></SENT>
<SENT sid="6" pm="."><plain>h(-1)  </plain></SENT>
<SENT sid="7" pm="."><plain>l(-1) by vildagliptin (n = 137) and increased by 3.8 +/- 1.7 pmol  </plain></SENT>
<SENT sid="8" pm="."><plain>h(-1)  </plain></SENT>
<SENT sid="9" pm="."><plain>l(-1) by <z:chebi fb="0" ids="5383">glimepiride</z:chebi> (n = 121) </plain></SENT>
<SENT sid="10" pm="."><plain>The between-group difference was 7.3 +/- 2.1 pmol  </plain></SENT>
<SENT sid="11" pm="."><plain>h(-1)  </plain></SENT>
<SENT sid="12" pm="."><plain>l(-1) (P &lt; 0.001) </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSIONS: Vildagliptin therapy but not <z:chebi fb="0" ids="5383">glimepiride</z:chebi> improves postprandial alpha-cell function, which persists for at least 2 years </plain></SENT>
</text></document>